Showing posts sorted by relevance for query breast cancer. Sort by date Show all posts
Showing posts sorted by relevance for query breast cancer. Sort by date Show all posts

Thursday, October 03, 2024

 

New ACS report: Breast cancer mortality continues three decade decline overall, but steeper increases in incidence for women <50 & Asian American, Pacific Islanders of all ages




American Cancer Society
ACS Breast Cancer Statistics Report 2024 

image: 

Breast Cancer Report from the American Cancer Society

view more 

Credit: American Cancer Society




The American Cancer Society (ACS) today released Breast Cancer Statistics, 2024, the organization’s biennial update on breast cancer occurrence and trends in the United States. The new report finds breast cancer mortality rates overall have dropped by 44% since 1989, averting approximately 517,900 breast cancer deaths. However, not all women have benefited from this progress, notably American Indian and Alaska Native (AIAN) women, whose rates have remained unchanged over the past three decades. Also concerning is the continued upward trend in breast cancer incidence, rising by 1% annually during 2012-2021, with the steepest increase in women younger than 50 years (1.4% per year) and Asian American/Pacific Islander (AAPI) women of any age (2.5%-2.7% per year). These important findings are published in CA: A Cancer Journal for Cliniciansalongside its consumer-friendly companion, Breast Cancer Facts & Figures 2024, available on cancer.org.

“The encouraging news is breast cancer mortality rates continue to decrease thanks to advances in early detection and treatment,” said Angela Giaquinto, associate scientist, cancer surveillance research at the American Cancer Society and lead author of the study. “But future progress may be thwarted by increasing incidence, especially among younger women, and consequences of the COVID-19 pandemic, such as delayed diagnosis due to interruptions in screening.”

Breast cancer is the most common cancer among U.S. women after skin cancer and the leading cause of cancer death in Hispanic women. In 2024, an estimated 310,720 new cases of invasive breast cancer will be diagnosed in women, and approximately 42,250 women are expected to die from the disease. While rare, this year, 2,790 men will also be diagnosed with breast cancer, and 530 men will die from the disease.

For the report, researchers analyzed population-based cancer incidence and mortality data collected by the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program, the Centers for Disease Control and Prevention’s National Program of Cancer Registries (NPCR), and the National Center for Health Statistics. Combined SEER and NPCR data provided by the North American Association of Central Cancer Registries (NAACCR) were the source for short-term incidence trends (1998-2021) and contemporary incidence rates (2017–2021) by race and ethnicity, age, molecular subtype, state, and stage (SEER Summary).

“Women today are a lot less likely to die from breast cancer, but alarming disparities still remain, especially for Asian American, Pacific Islander, Native American and Black women,” said Dr. William Dahut, chief scientific officer at the American Cancer Society. “These gaps need to be rectified through systematic efforts to ensure access to high-quality screening and treatment for every woman.”

Other key findings from the report include:

  • AIAN women have 10% lower breast cancer incidence than White women, but 6% higher mortality, and only 51% of AIAN women 40 years or older had a mammogram in the past two years compared to 68% of White women. 
  • Breast cancer in women under 50 years has increased in AAPI women by 50% since 2000, surpassing the rate in young Hispanic, AIAN, and Black women to become the highest rate alongside White women (both 86 per 100,000).
  • Black women continue to have a 38% higher breast cancer mortality rate than White women, despite a 5% lower incidence. Black women also have lower survival than White women for every breast cancer subtype and stage of diagnosis except localized disease, with which they are 10% less likely to be diagnosed (58% versus 68%).

To address ongoing cancer disparities in Black women, the ACS launched the VOICES of Black Women study in May 2024. The study aims to enroll over 100,000 Black women in the U.S. between the ages of 25 and 55 from diverse backgrounds and income levels who have not been diagnosed with cancer to better understand cancer risk and outcomes. For more information and to participate, visit voices.cancer.org.

“Building upon the progress we have made in reducing breast cancer mortality rates requires ensuring more individuals have access to breast cancer screenings,” said Lisa A. Lacasse, president of the American Cancer Society Cancer Action Network (ACS CAN), the advocacy affiliate of the American Cancer Society. “Through cooperative agreements with all 50 states, tribal organizations and territories, the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) has been a lifeline for limited-income, uninsured and underinsured women, providing them with critical screenings and treatment. Congress has a chance to pass the Screening for Communities to Receive Early and Equitable Needed Services (SCREENS) for Cancer Act, which would reauthorize the NBCCEDP and expand its reach to more people who may not otherwise be screened. We urge Congress to take this step towards saving lives from cancer while reducing costs for our health care system.”

Rebecca Siegel is senior author of the report. Other ACS authors participating in the study include Dr. Ahmedin JemalDr. Hyuna SungJessica Star and Dr. Robert Smith.

More information on breast cancer can be found here.

# # #

About the American Cancer Society
The American Cancer Society is the leading cancer-fighting organization with a vision to end cancer as we know it for everyone. For more than 110 years, we have been the only organization improving the lives of people with cancer and their families through advocacy, research, and patient support, to ensure that everyone has an opportunity to prevent, detect, treat, and survive cancer. To learn more, visit cancer.org or call our 24/7 helpline at 1-800-227-2345. Connect with us on Facebook, X, and Instagram.
 

Sunday, April 19, 2026

 

New guidance from ACP says all average-risk females aged 50-74 should undergo biennial mammography screening for breast cancer



ACP also offers screening advice for females aged 40-49, frequency of screening, discontinuing screening, and females with dense breasts





American College of Physicians





SAN FRANCISCO, April 17, 2026 – New guidance from the American College of Physicians (ACP) says all asymptomatic, average-risk females ages 50 to 74 should receive biennial screening mammography for breast cancer. Females between the ages of 40 and 49 should discuss with their doctor their risk for breast cancer and the benefits and harms of screening. This is because harms of screening such as false positive results, psychological distress because of it, overdiagnosis, overtreatment, additional testing, and radiation exposure may outweigh the uncertain benefits in this population. ACP's advice, "Screening for Breast Cancer in Asymptomatic, Average-Risk Adult Females: A Guidance Statement from the American College of Physicians", is published in Annals of Internal Medicine. 

ACP also provides guidance on when to discontinue breast cancer screening and how to approach screening for females with dense breasts. ACP says that asymptomatic, average‑risk females who are 75 years or older, or those with a limited life expectancy, discuss stopping routine screening with their doctor. This is because the benefits of screening beyond age 74 are reduced or uncertain, while potential harms, such as overdiagnosis, become more likely with increasing age. For asymptomatic, average‑risk females who have dense breasts, ACP advises doctors to consider supplemental digital breast tomosynthesis (DBT). Decisions should consider potential benefits and harms, radiation exposure, availability, patient values and preferences, and cost. However, ACP advises against using supplemental MRI or ultrasound for screening in this population. 

The guidance statement was developed by ACP’s Clinical Guidelines Committee which defined average risk as females who do not have a personal history of breast cancer or diagnosis of a high-risk breast lesion, a genetic mutation such as BRCA 1 or 2 that is known to increase risk, another familial breast cancer risk syndrome, or a history of high-dose radiation therapy to the chest at a young age. 

“Screening for breast cancer is essential and should be guided by the best available evidence" said Jason M. Goldman, MD, MACP, President of ACP. "ACP developed this guidance to provide physicians and females with the information they need to make breast cancer screening decisions, including when to start and discontinue, how often to screen, and which methods to use for screening."   

Saturday, March 08, 2025

 

Breast cancer death rates have stopped going down


\

Oxford University Press USA




A new paper in the Journal of Breast Imaging, published by Oxford University Press, indicates that breast cancer mortality rates have stopped declining in women older than age 74, and reconfirms that breast cancer mortality rates have stopped falling in women younger than age 40. This finding for older women is new.

Breast cancer is the second leading cause of cancer deaths in American women, with over 42,000 women dying of the disease in 2024. Before 1990, female breast cancer rates had been rising, and breast cancer mortality rates had been flat or increasing. Since 1990 there has been a steady decline in breast cancer mortality rates, which public health observers attribute both to the widespread use of mammograms and improvements in treatment.

The researchers, Debra Monticciolo and R. Edward Hendrick, assessed cancer mortality rates collected and maintained by the National Center for Health Statistics since 1990. For U.S. women overall breast cancer mortality rates have decreased steadily from 1990 to 2022, falling by 43.5% over that period. The most recent trend has been a decrease of 1.23% per year from 2010 to 2022, the lowest rate of decrease recorded since 1990. For U.S. women ages 20 to 39 (combining all races/ethnicities), breast cancer mortality rates decreased by 2.79% per year from 1990 until 2010, but have remained flat since 2010.

The investigation found that for women 75 years and older, the breast cancer mortality rate decreased by 1.26% per year from 1993 to 2013, when the rate stopped declining. For Asian, Hispanic, and Native American women (of all ages), breast cancer mortality rates have stopped declining over the most recent period: since 2009 for Asian women, since 2008 for Hispanic women, and since 2005 for Native American women.

Previous research indicated that breast cancer mortality rates stopped declining for women under 40 in 2010. The researchers here found that in both younger and older groups, the end of mortality rate decline was primarily due to mortality rates no longer declining for White women under 40 and over 74, as well as unfavorable trends for Hispanic women ages 20-39 years and for Asian, Hispanic, and Native American women 75 and older. Breast cancer mortality rates in Black women continued to decline in all age groups.

The investigators conducting this study contend that mortality rates have stopped declining for women under 40 and over 74 due to significant increases in stage IV breast cancers at diagnosis in these two age groups. Stage IV (metastatic) breast cancer at diagnosis has an extremely poor prognosis: a 31% 5-year survival rate.

This study indicates that increasing rates of advanced stage breast cancer at diagnosis is an important reason breast cancer mortality rates are no longer declining at the rate they once did. The researchers believe that this may be due to healthcare protocols. While the medical community currently recommends a breast cancer assessment for all women by age 25, breast cancer screening is only recommended for women under age 40 who are at higher-than-average risk. Some guidelines discourage women over 74 from screening.

Breast cancer mortality rate ratios for Black vs White women show the widest gap for women under age 40 years, suggesting that younger Black women are especially in need of alternatives to our current breast cancer risk assessment, screening, and treatment strategies, according to the authors.

“The fact that breast cancer mortality rates have stopped declining for women over age 74 is an alarming new trend,” said Monticciolo. “This is in addition to women under age 40 no longer seeing mortality rates decline from breast cancer. These groups are exactly those discouraged from breast cancer screening by some U.S. guidelines.”

The paper, “Recent Trends in Breast Cancer Mortality Rates for U.S. Women by Age and Race/Ethnicity,” is available (at midnight on March 6th) at https://doi.org/10.1093/jbi/wbaf007.

To request a copy of the study, please contact:
Daniel Luzer 
daniel.luzer@oup.com

Wednesday, October 18, 2023

 

Survey finds education is needed to identify lesser-known symptoms of breast cancer


The Ohio State University Comprehensive Cancer Center offers tips for taking action when breast changes are detected

Reports and Proceedings

OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

Dr. Pariser, MD, speaks with a patient 

IMAGE: 

ASHLEY PARISER, MD, SPEAKS WITH A PATIENT AT THE OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER—ARTHUR G. JAMES CANCER HOSPITAL AND RICHARD J. SOLOVE RESEARCH INSTITUTE ABOUT THE SUBTLE AND LESSER-KNOWN SYMPTOMS OF BREAST CANCER THAT WOMEN SHOULD BE AWARE OF.

view more 

CREDIT: THE OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER




COLUMBUS, Ohio -- An overwhelming majority of adults (93%) recognize a lump as a symptom of breast cancer, but less than half recognize other common symptoms associated with the disease, according to a consumer survey commissioned by The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James). 

Experts say this is very concerning, since most breast cancers do not present with a lump that can be detected by touch – and if they do, it often an indicates a fast-growing or advanced-stage cancer that is less treatable.

“Screening mammography is our No. 1 defense in detecting and addressing breast cancers at their earliest, most treatable stages, but it is also very important for people to be familiar with the look and feel of their own breast tissue so that sometimes subtle changes can be evaluated quickly to give us the best chance at early detection,” said Ashley Pariser, MD, a breast medical oncologist and director of breast cancer survivorship services at the OSUCCC – James. 

“We want people to feel empowered about their bodies and know what is normal for them. Many breast changes are the result of aging and childbirth; however, breast cancer can present in a number of ways,” said Pariser. “It is important that people feel safe to address these concerns in a timely way with their doctor. We have made great strides in detecting breast cancers in far earlier, more treatable stages.” 

These lesser-known symptoms of breast cancer include: 

  • retracted, inverted or downward-pointing nipple
  • breast puckering (an indentation that appears when you raise your arms)
  • loss of feeling in part of the breast
  • pitting/thickening of the skin on the breast
  • nipple discharge

In this new survey, just 31% of survey respondents recognized a retracted, inverted or downward-pointing nipple as a symptom of breast cancer, and just 39% recognized breast puckering as a symptom. Less than half of survey respondents were aware of loss of breast feeling (41%), pitting/thickening of the breast skin (45%) or nipple charge (51%) as concerns worthy of medical attention. 

Confusion about breast cancer screening guidelines 
Pariser noted that screening mammography remains the No. 1 tool for early detection, yet new survey results show that a third of women say they are confused about recommendations for breast cancer screenings, particularly those under age 30 (44%). 

“The best way for us to find breast cancer early is for women to present as soon as they notice a change, ideally even before they see a change. So that's why we recommend screening mammograms for those who qualify if we want to find breast cancer early,” said Pariser, who also is an assistant professor in the College of Medicine and an affiliate member of the Cancer Control Program at the OSUCCC – James. 

The American College of Radiology and American College of Obstetrics and Gynecologists recommend begin screening at age 40 for people of average risk. OSUCCC – James breast cancer experts encourage each person to talk with their physician about their personal cancer risk and family history to personalize their screening plan. 

Pariser notes that people with dense breast tissue should be closely monitored because they are at slightly higher risk and dense tissue can mask small tumors. Black and Ashkenazi Jewish people should also have a conversation about more intensive screening due to higher risk.  

‘Won’t happen to me’ mentality
According to the American Cancer Society, breast cancer remains the most common cancer diagnosed in women behind skin cancers, with just under 300,000 new cases and 43,000 deaths expected in 2023. This new consumer survey, however, shows that few believe they will get the disease, which afflicts about one in eight women. Among respondents, 75% of women and 91% of men don’t believe they will get breast cancer.

“So, although we are making great strides in terms of detection and treatment, unfortunately we live in a world where breast cancer is still a serious concern for people,” said Pariser. “Although the disease is less common in men, 1% of breast cancers occur in men. These cancers typically present as nipple changes, so it is also important that men feel empowered to seek medical attention for concerning symptoms, especially if they have a strong family history of breast cancer.” 

Study results and methodology
This study was conducted on behalf of The Ohio State University Wexner Medical Center/OSUCCC – James by SQL Server Reporting Services (SSRS) on its Opinion Panel Omnibus platform. The SSRS Opinion Panel Omnibus is a national, twice-per-month, probability-based survey. Data collection was conducted from Sept. 22-24 among a sample of 1,004 respondents. The survey was conducted via web (n=974) and telephone (n=30) and administered in English. The margin of error for total respondents is +/- 3.5 percentage points at the 95% confidence level. All SSRS Opinion Panel Omnibus data are weighted to represent the target population of U.S. adults ages 18 or older.

Breast cancer screening is available at more than a dozen locations across Columbus and the surrounding communities. To learn more about breast cancer treatment and research at the OSUCCC – James, visit cancer.osu.edu/breastcancer or call 1-800-293-5066. 

 

Most women know that a lump in the breast is cause for concern, but a new survey by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute finds education is needed about the lesser-known symptoms of breast cancer to help flag concerns, identify breast cancer as early as possible and initiate treatment.

CREDIT

The Ohio State University Comprehensive Cancer Center

Tuesday, September 01, 2020

Venom from honeybees found to kill aggressive breast cancer cells

Venom from honeybees found to kill aggressive breast cancer cells
Dr Ciara Duffy at the Harry Perkins Institute of Medical Research. Credit: Harry Perkins Institute of Medical Research
Using the venom from 312 honeybees and bumblebees in Perth Western Australia, Ireland and England, Dr. Ciara Duffy from the Harry Perkins Institute of Medical Research and The University of Western Australia, tested the effect of the venom on the clinical subtypes of breast cancer, including triple-negative breast cancer, which has limited treatment options.
Results published in the prestigious international journal npj Precision Oncology revealed that honeybee venom rapidly destroyed triple-negative breast  and HER2-enriched .
Dr. Duffy said the aim of the research was to investigate the anti-cancer properties of honeybee venom, and a component compound, melittin, on different types of breast cancer cells.
"No-one had previously compared the effects of honeybee venom or melittin across all of the different subtypes of breast cancer and normal cells.
"We tested honeybee venom on normal breast cells, and cells from the clinical subtypes of breast cancer: hormone receptor positive, HER2-enriched, and triple-negative breast cancer.
"We tested a very small, positively charged peptide in honeybee venom called melittin, which we could reproduce synthetically, and found that the synthetic product mirrored the majority of the anti-cancer effects of honeybee venom," Dr. Duffy said.
"We found both honeybee venom and melittin significantly, selectively and rapidly reduced the viability of triple-negative breast cancer and HER2-enriched breast cancer cells.
"The venom was extremely potent," Dr. Duffy said.
A specific concentration of honeybee venom can induce 100% cancer cell death, while having minimal effects on normal cells.
"We found that melittin can completely destroy cancer cell membranes within 60 minutes."
Melittin in honeybee venom also had another remarkable effect; within 20 minutes, melittin was able to substantially reduce the chemical messages of cancer cells that are essential to cancer cell growth and cell division.
"We looked at how honeybee venom and melittin affect the cancer signaling pathways, the chemical messages that are fundamental for cancer cell growth and reproduction, and we found that very quickly these signaling pathways were shut down.
"Melittin modulated the signaling in breast cancer cells by suppressing the activation of the receptor that is commonly overexpressed in triple-negative breast cancer, the epidermal growth factor receptor, and it suppressed the activation of HER2 which is over-expressed in HER2-enriched breast cancer," she said.
Western Australia's Chief Scientist Professor Peter Klinken said "This is an incredibly exciting observation that melittin, a major component of honeybee venom, can suppress the growth of deadly breast cancer cells, particularly .
"Significantly, this study demonstrates how melittin interferes with signaling pathways within breast cancer cells to reduce cell replication. It provides another wonderful example of where compounds in nature can be used to treat human diseases", he said.
Dr. Duffy also tested to see if melittin could be used with existing chemotherapy drugs as it forms pores, or holes, in breast cancer cell membranes, potentially enabling the entry of other treatments into the cancer cell to enhance cell death.
"We found that melittin can be used with  or chemotherapies, such as docetaxel, to treat highly-aggressive types of breast cancer. The combination of melittin and docetaxel was extremely efficient in reducing tumor growth in mice."
Dr. Duffy's research was conducted as part of her Ph.D. undertaken at Perth's Harry Perkins Institute of Medical Research at the Cancer Epigenetics laboratory overseen by A/Prof. Pilar Blancafort. "I began with collecting Perth honeybee venom. Perth bees are some of the healthiest in the world.
"The bees were put to sleep with carbon dioxide and kept on ice before the venom barb was pulled out from the abdomen of the bee and the venom extracted by careful dissection," she said.
While there are 20,000 species of bees, Dr. Duffy wanted to compare the effects of Perth honeybee venom to other honeybee populations in Ireland and England, as well as to the venom of bumblebees.
"I found that the European  in Australia, Ireland and England produced almost identical effects in  cancer compared to normal . However, bumblebee venom was unable to induce cell death even at very high concentrations.
One of the first reports of the effects of bee venom was published in Nature in 1950, where the  reduced the growth of tumors in plants. However, Dr. Duffy said it was only in the past two decades that interest grew substantially into the effects of  on different cancers.
In the future, studies will be required to formally assess the optimum method of delivery of , as well as toxicities and maximum tolerated doses
Bee venom may help treat eczema

More information: Ciara Duffy et al, Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer, npj Precision Oncology (2020). DOI: 10.1038/s41698-020-00129-0
Journal information: Nature